Metra Biosystems invests in Cholestech:
This article was originally published in Clinica
Executive Summary
Metra Biosystems will develop and market a cassette for Cholestech's LDX system to assess bone resorption. Metra, which has also made a "small equity investment" in Cholestech, will use its Pyrilinks-D urine assay for the new cassette. Additional equity investments will be made on completion of development milestones. Cholestech will market the assay in the US and both companies will distribute it internationally. The agreement between the two companies also provides for additional Metra assays to be added to the Cholestech system.
You may also be interested in...
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.